Clinical TrialID 7430
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
NCT05595460
SCLC,Extensive Stage
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final clinical_trial record.
- Clinical Trial Id
- 7430
- Evidence Id
- 7430
- Core Evidence Id
- 7430
- Source Clinical Trial Id
- 7426
- Herb2 Clinical Trial Id
- HBCT007426
- Nct Id
- NCT05595460
- Title
- Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
- Status
- Recruiting
- Phase
- Phase 1
- Study Result
- No
- Study Condition
- SCLC,Extensive Stage
- Study Type
- Interventional
- Study Design
- Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
- Intervention
- DRUG: RYZ101 Dose Level 1|DRUG: RYZ101 Dose Level 2|DRUG: RYZ101 Dose Level 3|DRUG: RYZ101 Dose Level -1|DRUG: Atezolizumab|DRUG: Carboplatin|DRUG: Etoposide
- Intervention Allocation
- Intervention Model
- Single_Group
- Intervention Mask
- Intervention Purpose
- Treatment
- Gender
- All
- Age
- Adult, Older_Adult
- Enrollment
- 31
- Outcome Measure
- RP2D, RP2D as determined by incidence rate of DLTs, 42 days of study treatment|Safety and tolerability of RYZ101 in combination with SoC, Safety and tolerability of RYZ101 in combination with SoC as measured by incidence and severity of AEs including SAEs, laboratory changes and other safety findings, Up to 50 months
- Sponsor Collaborator
- RayzeBio, Inc.
- Funded By
- INDUSTRY
- Location
- Research Facility, Los Angeles, California, 90024, United States|Research Facility, San Francisco, California, 94158, United States|Research Facility, Jacksonville, Florida, 32224, United States|Research Facility, Orlando, Florida, 32806, United States|Research Facility, Grand Rapids, Michigan, 49503, United States|Research Facility, Troy, Michigan, 48098, United States|Research Facility, Rochester, Minnesota, 55905, United States|Research Facility, Omaha, Nebraska, 68130, United States|Research Facility, Houston, Texas, 77090, United States|Research Facility, Salt Lake City, Utah, 84112, United States|Research Facility, San Juan, 00935, Puerto Rico
- Other Id
- RYZ101-101
- Start Date
- 2022-10-10
- Primary Completion Date
- 2025-03-01
- Completion Date
- 2026-12
- First Posted
- 2022-10-27
- Results First Posted
- Last Update Posted
- 2024-08-23
- Study Document
- Study Url
- https://clinicaltrials.gov/study/NCT05595460
- Title Cn
- Title En
- Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC
- Bilingual Status
- semi_complete